Status:
COMPLETED
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
Exclusion
- ECT in the last 6 months
- Substance abuse or dependence
- History of claustrophobia
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00986531
Start Date
November 1 2009
End Date
October 1 2011
Last Update
November 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States